MAR LUIS-HIDALGO

Dr. MAR LUIS-HIDALGO

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2015 in Transfusion
Verified
Journal Article
Closed access
PDF file
MÁManuel Álvarez
Manuel Álvarez
MLMAR LUIS-HIDALGO
MAR LUIS-HIDALGO
MBMaria Alma Bracho
Maria Alma Bracho
ABAmando Blanquer
Amando Blanquer
LLLuis Larrea
Luis Larrea
RRRoberto Roig
Roberto Roig


16 July 2025 in Cells
Verified
Journal Article
Open access
PDF file
MLMAR LUIS-HIDALGO
MAR LUIS-HIDALGO
JPJosé Luis Piñana
José Luis Piñana
CSCarlos Solano
Carlos Solano
DPDOLORES PLANELLES
DOLORES PLANELLES
This paper conducts a literature review on the role of natural killer cells in haploidentical hematopoietic stem cell transplantation. Theoretical concepts related to KIR genes are introduced regarding their structure, nomenclature, genetic organization, polymorphism, and inheritance pattern, types of KIR proteins and receptors, HLA ligands for KIR receptors, and the definition of different NK alloreactivity prediction models for the donor of haploidentical hematopoietic stem cell transplantation and the recipient. These models include the following and consider incompatibility: ligand–ligand, receptor–ligand, gene–gene, and KIR haplotype models or the KIR-B donor group. These models consider the presence or absence of specific ligands or receptors and/or KIR genes in the donor and recipient to predict alloreactivity. Determining the best model for predicting KIR alloreactivity and its significance in donor selection algorithms for haploidentical transplantation is still under investigation.


3 January 2020 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
MLMAR LUIS-HIDALGO
MAR LUIS-HIDALGO
DSDolores Planelles Silvestre
Dolores Planelles Silvestre
MGMaría Guzmán-Fulgencio
María Guzmán-Fulgencio
ECEmma Castro
Emma Castro
CSCarlos Solano
Carlos Solano

23 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
RNRut Meseguer Naturil
Rut Meseguer Naturil
Cristobal Aguilar-GallardoCristobal Aguilar-Gallardo
Cristobal Aguilar-Gallardo
PAPaula Amat
Paula Amat
LLLuis Larrea
Luis Larrea
ABAna Bonora-Centelles
Ana Bonora-Centelles
CSCarlos Solano
Carlos Solano
Background: Relapse and opportunistic viral infections remain major causes of treatment failure after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Adoptive transfer of natural killer (NK) cells is a promising strategy to enhance post-transplant immune reconstitution. Adaptive NKG2C+ NK cells exhibit enhanced cytotoxicity and persistence, but the influence of baseline donor immunophenotype on GMP manufacturing has not been systematically investigated. We evaluated whether donor NKG2A/NKG2C immunophenotypes are associated with successful manufacture of adaptive NK-cell products. Methods: Eighty-three healthy donors from the ReDoCel registry underwent immunophenotypic characterization of circulating NK-cell subsets by multiparametric flow cytometry. Donors were stratified by unsupervised hierarchical clustering according to NKG2A/NKG2C expression. Representative donors from NKG2C- and NKG2A-dominant clusters underwent feeder-free GMP-compliant expansion using the automated CliniMACS Prodigy® platform (Miltenyi Biotec, Bergisch Gladbach, Germany). Expanded products were evaluated for manufacturing efficiency, immunophenotype, cytotoxic function, and post-thaw stability. Results: Baseline NKG2C frequencies showed marked inter-donor variability, allowing identification of four immunophenotypic clusters. Only the NKG2C-dominant donor achieved successful GMP manufacturing, exceeding the predefined expansion threshold while maintaining high viability and purity. Both NKG2A-dominant donors showed limited proliferative capacity under identical manufacturing conditions. Expanded NK cells acquired an activated phenotype characterized by increased expression of DNAM-1, NKG2D, NKp30, NKp46, and TIM-3 while preserving mature differentiation and KIR expression. Functional analyses demonstrated potent degranulation against leukemia targets with minimal autoreactivity, resulting in a predominantly cytotoxic effector profile. The successfully expanded product maintained viability, phenotype, and function after long-term cryopreservation. Conclusions: This proof-of-concept study suggests that baseline donor NKG2A/NKG2C immunophenotype may influence GMP manufacturing of adaptive NK-cell products. These findings support prospective evaluation of donor immunophenotyping as a biomarker for donor qualification and manufacturing optimization to facilitate standardized off-the-shelf adaptive NK-cell therapies after allo-HSCT.